Ligand id: 9063

Name: enoximone

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: enoximone

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 83.5
Molecular weight 248.06
XLogP 2.71
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

1. Dage RC, Roebel LE, Hsieh CP, Weiner DL, Woodward JK. (1982)
Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one).
J. Cardiovasc. Pharmacol., 4 (3): 500-8. [PMID:6177949]
2. el Allaf D, D'Orio V, Carlier J. (1984)
The new inotropic phosphodiesterase inhibitors.
Arch. Int. Physiol. Biochim., 92 (4): S69-79. [PMID:6085243]
3. Roebel LE, Dage RC, Cheng HC, Woodward JK. (1982)
Characterization of the cardiovascular activities of a new cardiotonic agent, MDL 17043 (1,3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazole-2-one).
J. Cardiovasc. Pharmacol., 4 (5): 721-9. [PMID:6182401]
4. Venuti MC, Jones GH, Alvarez R, Bruno JJ. (1987)
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).
J. Med. Chem., 30 (2): 303-18. [PMID:3027339]
5. Weber KT, Janicki JS, Jain MC. (1986)
Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
J Heart Transplant, 5 (2): 105-12. [PMID:2956397]